Rockville, Maryland, United States · Hybrid
$100k–$120k/yr
Our Company NIT is a clinical-stage, T cell-focused biopharmaceutical company. Since its founding in 2014, NIT and its employees have been dedicated to advancing immuno-oncology and enhancing immunity against infectious …
Skills: Business Development, Due Diligence, Vendor Management, In-licensing, Market Analysis
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The Business Development Manager is responsible for executing key BD activities, managing due diligence, and identifying in-licensing opportunities. They also maintain corporate decks and support commercial operations through cross-functional partnerships.
A bachelor's degree is required, with a master's in science or business preferred, along with 3+ years of biopharmaceutical industry experience. Candidates should be detail-oriented self-starters with a preference for oncology experience and the ability to travel up to 20%.
Our Company
NIT is a clinical-stage, T cell-focused biopharmaceutical company. Since its founding in 2014, NIT and its employees have been dedicated to advancing immuno-oncology and enhancing immunity against infectious diseases. Supported by leading experts and key opinion leaders in industry and academia, we are investigating NT-I7, our lead product candidate, as a monotherapy and in combination with other immunotherapeutics. In addition, NIT is building commercial capabilities through Endari® (prescription-grade L-glutamine oral powder), an FDA-approved therapy indicated to reduce acute complications of sickle cell disease in adults and pediatric patients 5 years of age and older.
We Offer
Job Summary
The Business Development Manager will play a key role in maximizing relationships and creating long-term value for the company, its partners, and its patients.
Responsibilities
Qualifications
NeoImmuneTech, Inc. provides equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
If you require assistance to complete a job application, please email us at [email protected].
NIT is a clinical-stage T cell-focused biotech company dedicated to expanding the horizon of I-O and infectious diseases
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck and Roche for CPI combination trials. Follow us on X @neoimmunetech
Offices: 2400 Research Blvd., Suite 250, Rockville, MD 20850, US
View all jobs at NeoImmuneTechNIT is a clinical-stage T cell-focused biotech company dedicated to expanding the horizon of I-O and infectious diseases
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck and Roche for CPI combination trials. Follow us on X @neoimmunetech
Offices: 2400 Research Blvd., Suite 250, Rockville, MD 20850, US
View all jobs at NeoImmuneTech